119208-80-9

Basic information

• Product Name: N,N'-Bis<4-methoxybenzylidene>-4-methoxyphenylmethanediamine
• Synonyms: N,N'-Bis<4-methoxybenzylidene>-4-methoxyphenylmethanediamine
• CAS NO: 119208-80-9
• Molecular Weight: 388.466
• Mol File: 119208-80-9.mol
• Article Data: 21

Chemical Properties

• CAS DataBase Reference: N,N'-Bis<4-methoxybenzylidene>-4-methoxyphenylmethanediamine(CAS DataBase Reference)
• NIST Chemistry Reference: N,N'-Bis<4-methoxybenzylidene>-4-methoxyphenylmethanediamine(119208-80-9)
• EPA Substance Registry System: N,N'-Bis<4-methoxybenzylidene>-4-methoxyphenylmethanediamine(119208-80-9)

Safety Data

• Hazardous Substances Data: 119208-80-9(Hazardous Substances Data)

Upstream product

• 123-11-5 4-methoxy-benzaldehyde 
• 104-46-1 anethole 
• 102852-89-1 (2R,3R)-2-(4-Methoxy-benzyl)-3-phenyl-oxaziridine 

Downstream Products

• 51625-68-4 1,3,5-tris(3-nitrophenyl)-2,4-diazapenta-1,4-diene 
• 101718-75-6 3-amino-3-(4-methoxy-phenyl)-2-phenyl-propionic acid ethyl ester 
• 83810-03-1 2,4,8,10-Tetrakis-(4-methoxy-phenyl)-3,5,9-triaza-tricyclo[5.3.2.0^1,6]dodec-5-ene-7-carboxylic acid ethyl ester 
• 55407-47-1 2,4,6,8-tetrakis-(4-methoxy-phenyl)-3,7-diaza-bicyclo[3.3.1]nonan-9-one 
• 3424-93-9 4-methoxyphenylacetamide 
• 7753-12-0 2,4,6-tris-(4-methoxy-phenyl)-[1,3,5]triazine 
• 142683-08-7 2,5-di(4-methoxyphenyl)-3,3,4,4-tetracyanopyrrolidine 
• 2186-92-7 p-Anisaldehyde dimethyl acetal 
• 112129-06-3 N-chloro-4-methoxybenzenemethanimine 
• 623-12-1 4-chloromethoxybenzene 
• 112129-05-2 N-chloro-4-methylbenzenemethanimine 
• 206658-53-9 [1-(4-Methoxy-phenyl)-meth-(E)-ylidene]-[(4-methoxy-phenyl)-phenylsulfanyl-methyl]-amine 
• 1728-96-7 2,4,5-tris(4-methoxyphenyl)-1H-imidazole 
• 185460-00-8 5,6-tetramethylene-2-(p-methoxyphenyl)-3,3,4-tricyano-2,3,4,5-tetrahydropyridine-4-carboxamide 

Relevant articles and documents

Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1α pathway

Four series of hypoxia-inducible factor-1 alpha (HIF-1α) functioning derivatives stemming from modifications to the C-29 carboxyl group of celastrol were designed and synthesized, and their anticancer activities were evaluated. To address the structure and activity relationship of each derivative, extensive structural changes were made. HRE luciferase reporter assay demonstrated that 12 modified compounds showed superior HIF-1α inhibitory activity. Among them, compound C6 exhibited the best features: firstly, the strongest HIF-1α inhibitory activity (IC50 = 0.05 μM, 5-fold higher than that of celastrol); secondly, lower cytotoxicity (22-fold lower, C6-16.85 μM vs celastrol-0.76 μM). Thus, the safety factor of C6 was about 112 times higher than that of celastrol. Western blot assay indicated that C6 may inhibit the expression of HIF-1α protein in cells. Additionally, C6 hindered tumor cell cloning, migration and induced cell apoptosis. It is worth mentioning that in the mouse tumor xenograft model, C6 (10 mg/kg) displayed good antitumor activity in vivo, showing a better inhibition rate (74.03%) than the reference compound 5-fluorouracil (inhibition rate, 59.58%). However, the celastrol treatment group experienced collective death after four doses of the drug. Moreover, C6 minimally affected the mouse weight, indicating that its application in vivo has little toxic effect. H&E staining experiments show that it could also exacerbate the degree of tumor cell damage. The results of water solubility experiment show that the solubility of C6 is increased by 1.36 times than that of celastrol. In conclusion, C6 is a promising antitumor agent through HIF-1α pathway.

Synthesis of β-Phosphinolactams from Phosphenes and Imines

Various cis-β-phosphinolactams are synthesized stereoselectively for the first time from imines and diazo(aryl)methyl(diaryl)phosphine oxides under microwave irradiation. Diazo(aryl)methyl(diaryl)phosphine oxides first undergo the Wolf rearrangement to generate phosphenes. Imines nucleophilically attack the phosphenes followed by an intramolecular nucleophilic addition via less steric transition states to give final cis-β-phosphinolactams. C-Styrylimines generally give rise to β-phosphinolactams in higher yields than C-arylimines. The stereoselectivity and proposed mechanism are rationalized by DFT theoretical calculation.

2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation

Imidazoline-based small molecule inhibitors of p53-MDM2 interaction intended for the treatment of p53 wild-type tumors are the promising structures for design of anticancer drugs. Based on fragment approach we have investigated a key role of substituents